Literature DB >> 25270847

Burden of skeletal-related events in prostate cancer: unmet need in pain improvement.

M S Broder1, B Gutierrez, D Cherepanov, Y Linhares.   

Abstract

PURPOSE: Up to 75% of patients with prostate cancer experience metastatic bone disease, which leads to an increased risk for skeletal-related events (SREs) including pathological bone fracture, spinal cord compression, and hypercalcemia of malignancy. Our objective was to systematically review the literature on the impact of SREs on quality of life (QOL), morbidity, and survival with a primary focus on the impact of SREs on pain in prostate cancer patients.
METHODS: We searched PubMed, limiting to peer-reviewed English-language human studies published in 2000-2010. The search was based on the US Food and Drug Administration and European Medicines Agency definition of an SRE, which includes pathologic fracture, spinal cord compression (SCC), hypercalcemia of malignancy, and radiotherapy or surgery to bone resulting from severe bone pain.
RESULTS: A total of 209 articles were screened, of which 173 were excluded, and 36 were included in this review. Patients with SREs had more pain and worse survival compared with no SREs. Pathologic bone fractures worsened QOL and were associated with shorter survival. Radiation therapy of SCC alleviated pain and improved morbidity. SCC was associated with decreases in patient survival. Radiation therapy and surgery to bone improved pain.
CONCLUSIONS: Specific SREs are associated with worse outcomes, including increased pain, poorer QOL, morbidity, and survival. Treatment of SREs is associated with improved pain, although there remains a need for more effective treatment of SREs in prostate cancer patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25270847     DOI: 10.1007/s00520-014-2437-3

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  49 in total

1.  Systemic radionuclide therapy in pain palliation.

Authors:  Knut Liepe; Roswitha Runge; Jörg Kotzerke
Journal:  Am J Hosp Palliat Care       Date:  2005 Nov-Dec       Impact factor: 2.500

2.  Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.

Authors:  William F Hartsell; Charles B Scott; Deborah Watkins Bruner; Charles W Scarantino; Robert A Ivker; Mack Roach; John H Suh; William F Demas; Benjamin Movsas; Ivy A Petersen; Andre A Konski; Charles S Cleeland; Nora A Janjan; Michelle DeSilvio
Journal:  J Natl Cancer Inst       Date:  2005-06-01       Impact factor: 13.506

3.  Predictive implications of bone turnover markers after palliative treatment with (186)Re-HEDP in hormone-refractory prostate cancer patients with painful osseous metastases.

Authors:  Athanasios Zafeirakis; Georgios Papatheodorou; Athanasios Arhontakis; Athanasios Gouliamos; Lambros Vlahos; Georgios S Limouris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

4.  Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain.

Authors:  Oliver Sartor; Robert H Reid; David L Bushnell; Donald P Quick; Peter J Ell
Journal:  Cancer       Date:  2007-02-01       Impact factor: 6.860

Review 5.  Evolution of treatment options for patients with CRPC and bone metastases: bone-targeted agents that go beyond palliation of symptoms to improve overall survival.

Authors:  Kyle O Rove; E David Crawford
Journal:  Oncology (Williston Park)       Date:  2011-12       Impact factor: 2.990

6.  The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain.

Authors:  Knut Liepe; Roswitha Runge; Jörg Kotzerke
Journal:  J Cancer Res Clin Oncol       Date:  2004-09-22       Impact factor: 4.553

7.  What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?

Authors:  Stéphane Oudard; Eugeniu Banu; Jacques Medioni; Florian Scotte; Adela Banu; Eric Levy; Johana Wasserman; Gabriel Kacso; Jean-Marie Andrieu
Journal:  BJU Int       Date:  2009-02-06       Impact factor: 5.588

8.  Ten-year survival in patients with metastatic prostate cancer.

Authors:  Catherine M Tangen; James R Faulkner; E David Crawford; Ian M Thompson; Daisaku Hirano; Mario Eisenberger; Maha Hussain
Journal:  Clin Prostate Cancer       Date:  2003-06

9.  Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer.

Authors:  Venita DePuy; Kevin J Anstrom; Liana D Castel; Kevin A Schulman; Kevin P Weinfurt; Fred Saad
Journal:  Support Care Cancer       Date:  2007-07       Impact factor: 3.359

10.  Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer.

Authors:  S L Turner; S Gruenewald; N Spry; V Gebski
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

View more
  13 in total

1.  Radium-223 Inhibits Osseous Prostate Cancer Growth by Dual Targeting of Cancer Cells and Bone Microenvironment in Mouse Models.

Authors:  Mari I Suominen; Katja M Fagerlund; Jukka P Rissanen; Yvonne M Konkol; Jukka P Morko; ZhiQi Peng; Esa J Alhoniemi; Salla K Laine; Eva Corey; Dominik Mumberg; Karl Ziegelbauer; Sanna-Maria Käkönen; Jussi M Halleen; Robert L Vessella; Arne Scholz
Journal:  Clin Cancer Res       Date:  2017-03-31       Impact factor: 12.531

2.  Skeletal Complications and Mortality in Thyroid Cancer: A Population-Based Study.

Authors:  Palak Choksi; Maria Papaleontiou; Cui Guo; Francis Worden; Mousumi Banerjee; Megan Haymart
Journal:  J Clin Endocrinol Metab       Date:  2017-04-01       Impact factor: 5.958

3.  An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective.

Authors:  Alicia K Morgans; Thomas Hutson; Alice Kai Dan Guan; David Garcia; Anna Zhou; Edward Drea; Nicholas J Vogelzang
Journal:  BMC Health Serv Res       Date:  2022-07-14       Impact factor: 2.908

4.  Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.

Authors:  Aaron P Mitchell; Akriti Mishra Meza; Katherine S Panageas; Allison Lipitz-Snyderman; Peter B Bach; Michael J Morris
Journal:  J Natl Cancer Inst       Date:  2022-03-08       Impact factor: 11.816

Review 5.  Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss.

Authors:  Maria Rita Dionísio; André Mansinho; Catarina Abreu; Joana Cavaco-Silva; Sandra Casimiro; Luís Costa
Journal:  Br J Clin Pharmacol       Date:  2019-02-16       Impact factor: 4.335

6.  An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries.

Authors:  Jean-Jacques Body; Francesca Gatta; Erwin De Cock; Sunning Tao; Persefoni Kritikou; Pauline Wimberger; Jeroen Mebis; Marc Peeters; Paolo Pedrazzoli; Augusto Caraceni; Vincenzo Adamo; Guy Hechmati
Journal:  Support Care Cancer       Date:  2017-04-21       Impact factor: 3.603

7.  Harnessing the potential of therapeutic agents to safeguard bone health in prostate cancer.

Authors:  Kurt Miller; Günther G Steger; Daniela Niepel; Diana Lüftner
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-07-09       Impact factor: 5.554

8.  A real-world study assessing the use of bone-targeted agents and their impact on bone metastases in patients with prostate cancer treated in clinical practice in Europe.

Authors:  Jean-Jacques Body; Roger von Moos; Alex Rider; Pamela Hallworth; Debajyoti Bhowmik; Francesca Gatta; Guy Hechmati; Yi Qian
Journal:  J Bone Oncol       Date:  2018-12-18       Impact factor: 4.072

9.  Costs and Healthcare Resource Utilization Associated with Hospital Admissions of Patients with Metastatic or Nonmetastatic Prostate Cancer.

Authors:  Krishna Tangirala; Sreevalsa Appukkuttan; Stacey Simmons
Journal:  Am Health Drug Benefits       Date:  2019-10

10.  Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate.

Authors:  Hirotaka Miyashita; Christina Cruz; Vaibhav Patel
Journal:  Support Care Cancer       Date:  2021-08-10       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.